Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Gastroenterology Reports
Published in: Current Gastroenterology Reports 3/2011

01-06-2011

Current Approach to the Treatment of Achalasia

Authors: Joseph G. Cheatham, Roy K. H. Wong

Published in: Current Gastroenterology Reports | Issue 3/2011

Login to get access

Abstract

Achalasia is a primary esophageal motility disorder characterized by aperistalsis and incomplete or absent relaxation of the lower esophageal sphincter (LES). The cause of the disease remains elusive and there is no intervention that improves the esophageal body function. Currently, treatment options focus on palliation of symptoms by reducing the LES pressure. The most effective and well-tolerated treatments continue to be the laparoscopic Heller myotomy and endoscopic pneumatic dilation; however, newer techniques (eg, peroral endoscopic myotomy and self-expanding metal stents) show promise. Botulinum toxin and pharmacologic therapy are reserved for those who are unable to undergo more effective therapies. Treatment options should be tailored to the patient, using current predictors of outcome such as the patient’s age and post-treatment LES pressures. The aim of this article is to highlight current literature and provide an up-to-date approach to the treatment of achalasia.
Literature
1.
Mayberry JF. Epidemiology and demographics of achalasia. Gastrointest Endosc Clin N Am. 2001;11(2):235–48. v.PubMed
2.
Leeuwenburgh I, Scholten P, Alderliesten J, et al. Long-term esophageal cancer risk in patients with primary achalasia: a prospective study. Am J Gastroenterol. 2010;105(10):2144–9.PubMedCrossRef
3.
Bortolotti M. Medical therapy of achalasia: a benefit reserved for few. Digestion. 1999;60(1):11–6.PubMedCrossRef
4.
Gelfond M, Rozen P, Gilat T. Isosorbide dinitrate and nifedipine treatment of achalasia: a clinical, manometric and radionuclide evaluation. Gastroenterology. 1982;83(5):963–9.PubMed
5.
Bortolotti M, Mari C, Lopilato C, et al. Effects of sildenafil on esophageal motility of patients with idiopathic achalasia. Gastroenterology. 2000;118(2):253–7.PubMedCrossRef
6.
Eherer AJ, Schwetz I, Hammer HF, et al. Effect of sildenafil on oesophageal motor function in healthy subjects and patients with oesophageal motor disorders. Gut. 2002;50(6):758–64.PubMedCrossRef
7.
Pasricha PJ, Ravich WJ, Hendrix TR, et al. Intrasphincteric botulinum toxin for the treatment of achalasia. N Engl J Med. 1995;332(12):774–8.PubMedCrossRef
8.
Pasricha PJ, Rai R, Ravich WJ, et al. Botulinum toxin for achalasia: long-term outcome and predictors of response. Gastroenterology. 1996;110(5):1410–5.PubMedCrossRef
9.
Annese V, Bassotti G, Coccia G, et al. A multicentre randomised study of intrasphincteric botulinum toxin in patients with oesophageal achalasia. GISMAD Achalasia Study Group Gut. 2000;46(5):597–600.
10.
Kolbasnik J, Waterfall WE, Fachnie B, et al. Long-term efficacy of Botulinum toxin in classical achalasia: a prospective study. Am J Gastroenterol. 1999;94(12):3434–9.PubMedCrossRef
11.
D’Onofrio V, Miletto P, Leandro G, Iaquinto G. Long-term follow-up of achalasia patients treated with botulinum toxin. Dig Liver Dis. 2002;34(2):105–10.PubMedCrossRef
12.
Tuset JA, Lujan M, Huguet JM, et al. Endoscopic pneumatic balloon dilation in primary achalasia: predictive factors, complications, and long-term follow-up. Dis Esophagus. 2009;22(1):74–9.PubMedCrossRef
13.
Kroupa R, Hep A, Dolina J, et al. Combined treatment of achalasia—botulinum toxin injection followed by pneumatic dilatation: long-term results. Dis Esophagus. 2010;23(2):100–5.PubMedCrossRef
14.
Vela MF, Richter JE, Khandwala F, et al. The long-term efficacy of pneumatic dilatation and Heller myotomy for the treatment of achalasia. Clin Gastroenterol Hepatol. 2006;4(5):580–7.PubMedCrossRef
15.
Radaelli F, Paggi S, Terreni N, et al. Acute reversible gastroparesis and megaduodenum after botulinum toxin injection for achalasia. Gastrointest Endosc. 2010;71(7):1326–7.PubMedCrossRef
16.
O’Connor JB, Singer ME, Imperiale TF, et al. The cost-effectiveness of treatment strategies for achalasia. Dig Dis Sci. 2002;47(7):1516–25.PubMedCrossRef
17.
Vaezi MF, Richter JE. Current therapies for achalasia: comparison and efficacy. J Clin Gastroenterol. 1998;27(1):21–35.PubMedCrossRef
18.
Kadakia SC, Wong RK. Graded pneumatic dilation using Rigiflex achalasia dilators in patients with primary esophageal achalasia. Am J Gastroenterol. 1993;88(1):34–8.PubMed
19.
• Hulselmans M, Vanuytsel T, Degreef T, et al.: Long-term outcome of pneumatic dilation in the treatment of achalasia. Clin Gastroenterol Hepatol. 2010;8(1):30–5. This study by Hulselmans et al. clearly outlines a successful pneumatic dilation technique based on a measured LES pressure endpoint that leads to long-term success rates. It also strongly substantiates prior findings that older populations are more likely to respond to pneumatic dilation and younger populations are likely to fail this therapeutic intervention. PubMedCrossRef
20.
Campos GM, Vittinghoff E, Rabl C, et al. Endoscopic and surgical treatments for achalasia: a systematic review and meta-analysis. Ann Surg. 2009;249(1):45–57.PubMedCrossRef
21.
Zerbib F, Thetiot V, Richy F, et al. Repeated pneumatic dilations as long-term maintenance therapy for esophageal achalasia. Am J Gastroenterol. 2006;101(4):692–7.PubMedCrossRef
22.
Eckardt VF, Aignherr C, Bernhard G. Predictors of outcome in patients with achalasia treated by pneumatic dilation. Gastroenterology. 1992;103(6):1732–8.PubMed
23.
Ponce J, Garrigues V, Pertejo V, et al. Individual prediction of response to pneumatic dilation in patients with achalasia. Dig Dis Sci. 1996;41(11):2135–41.PubMedCrossRef
24.
Vela MF, Richter JE, Wachsberger D, et al. Complexities of managing achalasia at a tertiary referral center: use of pneumatic dilatation, Heller myotomy, and botulinum toxin injection. Am J Gastroenterol. 2004;99(6):1029–36.PubMedCrossRef
25.
Sharma P, Kozarek R. Role of esophageal stents in benign and malignant diseases. Am J Gastroenterol. 2010;105(2):258–73. quiz 74.PubMedCrossRef
26.
Howard JM, Mongan AM, Manning BJ, et al. Outcomes in achalasia from a surgical unit where pneumatic dilatation is first-line therapy. Dis Esophagus. 2010;23(6):465–72.PubMedCrossRef
27.
Moawad FJ, Maydonovitch CL, Horwhat JD, Wong RK. Complications with pneumatic dilation. Clin Gastroenterol Hepatol. 2010;8(8):734–5. author reply 5.PubMedCrossRef
28.
Zhu YQ, Cheng YS, Tang GY, et al. Comparison of temporary stent insertion with pneumatic dilation of the same diameter in the treatment of achalasia patients: a retrospective study. J Gastroenterol Hepatol. 2010;25(3):499–505.PubMedCrossRef
29.
Zhao JG, Li YD, Cheng YS, et al. Long-term safety and outcome of a temporary self-expanding metallic stent for achalasia: a prospective study with a 13-year single-center experience. Eur Radiol. 2009;19(8):1973–80.PubMedCrossRef
30.
Li YD, Cheng YS, Li MH, et al. Temporary self-expanding metallic stents and pneumatic dilation for the treatment of achalasia: a prospective study with a long-term follow-up. Dis Esophagus. 2010;23(5):361–7.PubMed
31.
De Palma GD, Lovino P, Masone S, et al. Self-expanding metal stents for endoscopic treatment of esophageal achalasia unresponsive to conventional treatments. Long-term results in eight patients. Endoscopy. 2001;33(12):1027–30.PubMedCrossRef
32.
Tsiaoussis J, Pechlivanides G, Gouvas N, et al. Patterns of esophageal acid exposure after laparoscopic Heller’s myotomy and Dor’s fundoplication for esophageal achalasia. Surg Endosc. 2008;22(6):1493–9.PubMedCrossRef
33.
Rebecchi F, Giaccone C, Farinella E, et al. Randomized controlled trial of laparoscopic Heller myotomy plus Dor fundoplication versus Nissen fundoplication for achalasia: long-term results. Ann Surg. 2008;248(6):1023–30.PubMedCrossRef
34.
Boeckxstaens GE, Annese V, Bruley des Varannes S, et al. The European achalasia trial: a randomized multi-centre trial comparing endoscopic pneumodilation and laparoscopic myotomy as primary treatment of idiopathic achalasia. Gastroenterology. 2010;138(Supplemental 1):s53.
35.
Zaninotto G, Costantini M, Rizzetto C, et al. Four hundred laparoscopic myotomies for esophageal achalasia: a single centre experience. Ann Surg. 2008;248(6):986–93.PubMedCrossRef
36.
Eldaif SM, Mutrie CJ, Rutledge WC, et al. The risk of esophageal resection after esophagomyotomy for achalasia. Ann Thorac Surg. 2009;87(5):1558–62. discussion 62–3.PubMedCrossRef
37.
• Inoue H, Minami H, Kobayashi Y, et al.: Peroral endoscopic myotomy (POEM) for esophageal achalasia. Endoscopy 2010;42(4):265–71. This study of a novel treatment for achalasia is the largest to date demonstrating excellent short-term outcomes from POEM and raising the expectations of positive results from larger studies with long-term outcomes.
38.
Perretta S, Dallemagne B, Allemann P, Marescaux J. Multimedia manuscript. Heller myotomy and intraluminal fundoplication: a NOTES technique. Surg Endosc. 2010;24(11):2903.PubMedCrossRef
Metadata
Title
Current Approach to the Treatment of Achalasia
Authors
Joseph G. Cheatham
Roy K. H. Wong
Publication date
01-06-2011
Publisher
Current Science Inc.
Published in
Current Gastroenterology Reports / Issue 3/2011
Print ISSN: 1522-8037
Electronic ISSN: 1534-312X
DOI
https://doi.org/10.1007/s11894-011-0190-z

Other articles of this Issue 3/2011

Current Gastroenterology Reports 3/2011 Go to the issue

ReviewPaper

Obesity and GERD: Pathophysiology and Effect of Bariatric Surgery

ReviewPaper

Growth Assessment in Clinical Practice: Whose Growth Curve?

ReviewPaper

Exploring the Differential Diagnosis of Joint Complaints in Pediatric Patients with Inflammatory Bowel Disease

ReviewPaper

Recent Progress in Congenital Diarrheal Disorders

ReviewPaper

Evaluation of Patients with Suspected Laryngopharyngeal Reflux: A Practical Approach

ReviewPaper

Intestinal Obstruction Syndromes in Cystic Fibrosis: Meconium Ileus, Distal Intestinal Obstruction Syndrome, and Constipation
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits